Clinical Trial Update: Vitamin K2 Supplementation to Activate Matrix Gla Protein (MGP) as Endogenous Inhibitor of Vascular Calcification in Hemodialysis Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Vitamin K2 (menaquinone) supplementation to activate matrix Gla protein as an endogenous inhibitor of vascular calcification in patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• Vitamin K2 (menaquinone)

Snippet

Sponsor: RWTH Aachen University | Conditions: CKD 5D, Hemodialysis | Phase 3 | Status: COMPLETED